Janus Henderson Group’s IVERIC bio ISEE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-156,831
Closed -$6.17M – 2634
2023
Q2
$6.17M Sell
156,831
-4,530,378
-97% -$160M ﹤0.01% 803
2023
Q1
$114M Buy
4,687,209
+133,305
+3% +$2.92M 0.08% 231
2022
Q4
$97.5M Sell
4,553,904
-559,587
-11% -$11.9M 0.07% 241
2022
Q3
$91.7M Sell
5,113,491
-3,036,228
-37% -$39.9M 0.07% 248
2022
Q2
$78.4M Buy
8,149,719
+6,704,654
+464% +$84.2M 0.05% 295
2022
Q1
$24.3M Buy
1,445,065
+1,433,850
+12,785% +$21.2M 0.01% 703
2021
Q4
$188K Buy
+11,215
New +$184K ﹤0.01% 2410

Janus Henderson Group's ISEE Position: Q3 2023 in Review

Janus Henderson Group sold out of IVERIC bio (ISEE) in Q3 2023, closing a stake of 156,831 shares — an estimated $6.17M sold.

Janus Henderson Group first reported a position in ISEE in Q4 2021 and held it in 7 quarters. The position peaked at $114M in Q1 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

  • Janus Henderson Group reported no remaining IVERIC bio position as of Q3 2023 after selling out during the quarter.
  • Janus Henderson Group sold 156,831 IVERIC bio shares in Q3 2023, an estimated $6.17M.
  • Janus Henderson Group first reported a position in IVERIC bio in Q4 2021 and held it in 7 quarters.
  • Janus Henderson Group's IVERIC bio position peaked at $114M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held IVERIC bio as of Q3 2023.

Based on Janus Henderson Group's 13F filing for Q3 2023, filed 14 Nov 2023.